Last updated: February 20, 2026
Flurbiprofen sodium, a nonsteroidal anti-inflammatory drug (NSAID), is supplied by multiple pharmaceutical manufacturers globally. Major suppliers include both active pharmaceutical ingredient (API) producers and finished drug manufacturers. Their geographical distribution spans North America, Europe, and Asia, with some focusing on bulk API production and others on formulation.
Key API Suppliers for Flurbiprofen Sodium
| Supplier Company |
Location |
API Production Capacity |
Quality Certifications |
Notable Markets |
| Pfizer Inc. |
United States |
High |
FDA, GMP compliant |
US, global |
| Jiangsu Hengrui Medicine |
China |
Moderate to high |
GMP, ISO 9001, ISO 14001 |
China, Asia, exports abroad |
| Zhejiang Huahai Pharmaceutical |
China |
High |
GMP, ISO 9001 |
Asia, Middle East, Africa |
| Granules India Ltd. |
India |
Moderate |
GMP, WHO-GMP |
India, exporting globally |
| Solara Active Pharma Sciences |
India |
Moderate to high |
GMP, ISO 9001, ISO 14001 |
India, Middle East, Europe, US |
Finished Dosage Form Suppliers
Manufacturers producing final formulations containing flurbiprofen sodium include:
- Mylan (now part of Viatris): Offers injectable and solid dosage forms.
- Teva Pharmaceuticals: Supplies oral tablets and topical formulations.
- Sandoz (Novartis): Produces various NSAID formulations.
- Zydus Cadila: Offers flurbiprofen sodium-based products in India.
Regulatory and Certification Standards
Suppliers adhere to global standards to meet regulatory requirements:
- Good Manufacturing Practice (GMP) certifications.
- International standards including ISO 9001 and ISO 14001.
- Approval from regulatory authorities such as the FDA and EMA for API production.
Market Share and Regional Focus
China and India dominate API production, providing cost advantages and substantial export volumes. North American and European companies primarily handle high-quality finished formulations, emphasizing regulatory compliance.
Supply Chain Dynamics
The API market for flurbiprofen sodium is characterized by:
- Consolidation among Asian API producers.
- Increased investment in GMP-certified facilities.
- Growing export volumes from Indian and Chinese suppliers.
- Supply disruptions caused by manufacturing shutdowns or regulatory audits have impacted global availability.
Impact on Sourcing Strategies
- Companies seeking cost-effective API options often turn to Chinese and Indian suppliers.
- High-quality API sourcing from Western suppliers is preferred for regulatory submissions in stringent markets.
- Variability in supply quality warrants rigorous qualification processes for API vendors.
Key Takeaways
- The API manufacturing landscape for flurbiprofen sodium primarily involves Chinese and Indian producers.
- Western companies like Pfizer maintain in-house manufacturing or quality control for finished products.
- Supply chain reliability depends on geopolitical, regulatory, and capacity factors.
- Certification standards are critical for regulatory approval in target markets.
- The global market continues to see growth driven by demand for NSAID formulations.
FAQs
1. Who are the leading API suppliers for flurbiprofen sodium?
Leading API producers include Jiangsu Hengrui Medicine, Zhejiang Huahai Pharmaceutical, and Granules India Ltd.
2. Which countries dominate the production of flurbiprofen sodium API?
China and India collectively account for the majority of world API production for flurbiprofen sodium.
3. Are there regulatory concerns with sourcing from Asian API suppliers?
Regulatory authorities like the FDA and EMA require GMP compliance and certification. Suppliers with recognized certifications satisfy regulatory standards.
4. What is the role of finished dosage form manufacturers?
They convert API into marketed products such as tablets and topical formulations, primarily in the US, Europe, and emerging markets.
5. How does supply chain stability influence sourcing decisions?
Supply disruptions can delay drug availability; companies often diversify suppliers and verify quality standards to mitigate risks.
References
- U.S. Food and Drug Administration. (2022). Pharmaceutical Good Manufacturing Practice (GMP) Regulations. https://www.fda.gov/drugs/pharmaceutical-quality-resources/drug-api-manufacturing-and-registration.
- International Organization for Standardization. (2019). ISO 9001 Quality Management Systems. https://www.iso.org/iso-9001-quality-management.html.
- European Medicines Agency. (2021). EMA Certification Standards for Active Substance Manufacturers. https://www.ema.europa.eu/en/human-regulatory/research-development/quality-industrial-processes/certification.
- ICIS. (2020). Global API Market for NSAIDs. https://www.icis.com/explore/chemicals/market-analysis/
- Pharmacore. (2022). Global API Manufacturers Database. https://pharmacore.com/database
[1] Food and Drug Administration. (2022). Pharmaceutical GMP Regulations.
